Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio
Aiming To Challenge Pfizer In Cardiomyopathy
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.
You may also be interested in...
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.